Navigation Links
Top Five International Pharmaceutical Company Awards Comprehensive Cardiac Safety Study to iCardiac
Date:11/11/2009

Positions iCardiac as technology leader in global ECG core lab market with largest number of highly automated QT(sm) studies.

Rochester, NY (PRWEB) November 11, 2009 -- iCardiac Technologies, Inc., a global leader in advanced cardiac core lab services and QT analysis, announced today that a top five pharmaceutical company has awarded iCardiac a comprehensive "Thorough QT" (TQT) study. iCardiac will provide end-to-end study management, international equipment deployment and scientific reporting, as well as advanced ECG analytics. The study will utilize iCardiac's Highly Automated QT and Dynamic QT beat-to-beat(sm) service offerings to dramatically improve study precision and reduce false positives and negatives.

"iCardiac's ability to reduce sample size as well as false positives in TQT studies continues to be well received by the pharmaceutical industry," said Sasha Latypova, Executive Vice President. "As these methods are now accepted as part of the regulatory review of cardiac safety, we expect the speed of adoption to continue to accelerate."

In October 2005, the FDA introduced a new guidance for industry (ICH E14) requiring the evaluation of pro-arrhythmic potential of new drugs by measuring the QT segment of ECGs collected in clinical trials. The dissatisfaction among pharmaceutical developers with the poor precision, high rate of false positives/negatives and high cost of the "gold standard" manual or semi-automated QT measurements has lead to efforts toward providing more advanced cardiac safety analytics.

About iCardiac Technologies
iCardiac Technologies, Inc. is a technologically-differentiated global cardiac core lab providing the industry's most sophisticated ICH E14 compliant cardiac safety assessment methodologies for Phase I through Phase IV studies, supported by expert scientific consultation, end-to-end project management, worldwide site and equipment logistics, 24/7 customer support and regulatory data submission. iCardiac's analysis services provide drug developers with more precise and cost-effective methods for ECG interval measurements, including Highly Automated QT, which is the market leading solution for automated evaluation of QT intervals for regulatory submissions. In addition, iCardiac provides Beyond QTsm, a suite of advanced ECG-based cardiac safety markers that have been accepted and used as a secondary end-point in regulatory approvals, and which delivers a more accurate assessment of the cardiac safety profile of drugs in development. iCardiac's COMPAS technology has been used for over a decade in cardiac clinical trials conducted for and by leading large and medium sized pharmaceutical, biotechnology and medical device companies. For more information, visit: www.icardiac.com.

###

Read the full story at http://www.prweb.com/releases/automated/thorough_qt/prweb3116734.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. Tyco International Reports Fourth Quarter Earnings From Continuing Operations Before Special Items of $0.61 Per Share and GAAP Earnings of $0.44 Per Share
2. Phoenix House Appoints Dr. Deni Carise as Chief Clinical Officer - Internationally Recognized Leader in Substance Abuse Treatment and Research
3. Tyco International to Present at the Citi Industrial Manufacturing & Transportation Conference
4. AirMed International, Top U.S. Air Ambulance, Receives EURAMI Accreditation
5. HUYA Bioscience International Establishes Strategic Partnership with School of Medicine and Pharmacy, Ocean University of China
6. Allied Worlds Nicole Baummer and Marjorie Thompson to Speak at PLUS International Conference
7. Service Corporation International Announces Third Quarter 2009 Financial Results
8. Stenum Hospital Kicks off International Rollout of M6 Artificial Lumbar Disc Replacement Surgery
9. FDA CONSUMER HEALTH INFORMATION UPDATES: Fraudulent H1N1 flu products, hearing aids, sound amplifiers, tobacco regulation, FDAs international posts, LASIK eye surgery, and FDA MedWatch safety alerts
10. Service Corporation International Announces Schedule for Its Third Quarter 2009 Earnings Release and Conference Call
11. Blue Cross and Blue Shield of Floridas Power of the Human Voice Campaign Wins Prestigious DMA International ECHO Gold Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... May 05, 2016 , ... If you don’t mind a bit of prickly ... may want to consider a treatment that some have called the next great tool ... , Microneedling, also known as skin needling, is a procedure using a device covered ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... Medical Society of Northern Virginia, Announces DoctorsTelemed?, A telehealth solution powered ... of Northern Virginia (MSNVA) launches DoctorsTelemed?, a telemedicine solution that uses CloudVisit’s ...
(Date:5/5/2016)... ... May 05, 2016 , ... Augusta Public Schools has teamed with ... partnership will enable school health offices to streamline and bolster care for district students. ... east of Wichita. Augusta public schools serve 2,300 students among its six schools. ...
(Date:5/5/2016)... ... 2016 , ... The Wisconsin Independent Private Practice Alliance (WIPPA/aka ... WCS, has been selected by the Wisconsin Physical Therapy Association (WPTA) as this ... is awarded annually to a member of the WPTA to recognize a Wisconsin ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... patented products, announces the Everlasting Glove, a sports invention that aids in the ... Sporting Goods Manufacturing industry is worth $9 billion," says Scott Cooper, CEO and ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... , May 4, 2016  It,s time for an upgrade. There are many ... a brilliant 3.5 inch LCD, the illustrious DVMAXX HD  offers unparalleled connectivity and ... well as a world class manufacturer of innovative technology.  Photo - ... ... ...
(Date:5/4/2016)... , May 4, 2016 ... of Jerusalem announced today that it had signed ... BioTheryX, Inc. , developer of novel protein degradation and ... development and commercialization of drug candidates representing first-in-class therapy ... license were not disclosed. The novel technology ...
(Date:5/4/2016)... DUBLIN , May 4, 2016 /PRNewswire/ ... the addition of the  "Global Multiple Myeloma ...  report to their offering.       ... Multiple Myeloma Market and Competitive Landscape Highlights ... pipeline products, Multiple Myeloma epidemiology, Multiple Myeloma ...
Breaking Medicine Technology: